Use of picria fel-terrae aglycone I in preparation of multidrug resistance reversal agent for tumors

A scrophularigenin aglycone and drug resistance reversal technology, applied in the field of medicine, can solve problems such as regulation that have not yet been reported, and achieve the effects of overcoming drug resistance, enhancing therapeutic effect, and obvious tumor suppressing effect.

Inactive Publication Date: 2014-12-24
FUDAN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] So far, there has been no report on the regulation of the drug resistance of scrophulariacetin Ⅰ on tumor cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of picria fel-terrae aglycone I in preparation of multidrug resistance reversal agent for tumors
  • Use of picria fel-terrae aglycone I in preparation of multidrug resistance reversal agent for tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Implementation 1: CCK-8 kit detects drug-resistant cell line resistance to glucosphrine aglycone Ⅰ

[0049] Experimental Materials:

[0050] Scrophulariae aglycone Ⅰ is extracted from Scrophulariae scrophulariae with a purity of not less than 95%. Human oral cancer cell line KB and its drug-resistant cell line KB / VCR were provided by the Chinese Academy of Sciences, human breast cancer cell line MCF-7 / ADR and its drug-resistant cell line MCF-7 / ADR, human colon cancer HCT-8 and The drug-resistant cell line HCT-8 / VCR was purchased from Nanjing Kaiji Biological Company. Verapamil (VPL), vincristine (VCR) and doxorubicin (ADR) were purchased from Roche Chemical Company with a purity greater than 99%. CCK-8 kit was purchased from Tongren Company.

[0051]

[0052] experimental method:

[0053] Cell recovery

[0054] 1) Take out the cryotube from the liquid nitrogen tank, put it directly into warm water at 37°C, and shake it from time to time to melt it as soon as pos...

Embodiment 2

[0080] Example 2: CCK-8 method detects the reversing effect of crocodile aglycone Ⅰ on the multidrug resistance activity of tumor cells

[0081] Experimental materials: Sophoraglycone Ⅰ was purchased from the Institute of Materia Medica, Chinese Academy of Sciences, with a purity of not less than 98%. All the other are with embodiment 1.

[0082] experimental method:

[0083] Sensitization experiment of acrogenin Ⅰ: KB / VCR, MCF-7 / ADR and HCT-8 / VCR cells were inoculated into 96-well plates at a density of 3500 / well, and after 24 h, different concentrations of VCR and different concentrations The VCR and matrine aglycone Ⅰ were prepared together with α-MEM containing 10% fetal bovine serum and added to each well. After culturing for 48 h, the culture medium was discarded, and the CCK-8 kit was used to measure the activity of the drug-resistant cell line and its parental cells to VCR and VCR + scrophginin I in the same manner as in Example 1, and a curve was drawn. Three rep...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicines, relates to an application of picria fel-terrae aglycone I in preparation of an anti-tumor drug, and particularly relates to an application of the picria fel-terrae aglycone I in preparation of a multidrug resistance reversal agent for tumors. The picria fel-terrae aglycone I is a natural product, has the effect of reversing multidrug resistance of tumor cells, can be used as a multidrug resistance reversal agent for tumors, also has the effects of increasing the sensibility of the multidrug resistance cells for tumors on the anti-tumor drug, and can be used as a chemosensitizer. The invention also provides a medication method of a pharmaceutical composition combined with the antitumor drug and the picria fel-terrae aglycone I for inhibiting multidrug resistance cell proliferation of the tumors. The picria fel-terrae aglycone I is developed as a novel anti-tumor drug or other auxiliary components thereof, and is significant in tumor suppression effect, and new path and means are provided for tumor treatment and curing.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to reversing multi-drug resistance of tumors and sensitizing anti-tumor drugs, and specifically relates to the new application of acrogenin I, that is, the use of arogenin I in preparing tumor multidrug reversal agents and antitumor agents. Application in tumor drug sensitizers. Background technique [0002] Malignant tumors seriously endanger human life and health, and have become one of the main causes of death from diseases today. At present, the main treatment methods for malignant tumors include surgery, radiotherapy and chemotherapy. Chemotherapy is a better option for patients diagnosed with advanced tumors and those with metastases. Clinicians can optimize the maximum curative effect and minimum toxicity by adjusting the dosage of drugs, helping patients prolong survival time and improve the prognosis of life quality. However, the generation of drug resistance of tumor cells leads t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61K31/704A61P35/00
Inventor 余龙朱恒锐
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap